Recently the Australian Asbestos Diseases Research Institute (ADRI) and EnGeneIC announced very promising first results from a MesomiR-1 Phase 1 Trial in Late Stage Mesothelioma patients. This development could give more hope to patients of asbestos cancer for long-term survival.
Click here to watch an impressive news item on the Today Show of July 12.
Last May The European Asbestos Forum awarded Professor Nico van Zandwijk, Director of the ADRI, with the Dr. J. Stumphius Recognition Award for his groundbreaking research. The trial is a cooperative project.